dc.contributor.author |
Dube, A
|
|
dc.contributor.author |
Semete-Makokotlela, Boitumelo
|
|
dc.contributor.author |
Ramalapa, Bathabile E
|
|
dc.contributor.author |
Reynolds, J
|
|
dc.contributor.author |
Boury, F
|
|
dc.contributor.editor |
Glover, RL |
|
dc.contributor.editor |
Nyanganyura, D |
|
dc.contributor.editor |
Mufamadi, MS |
|
dc.contributor.editor |
Mulaudzi, RB |
|
dc.date.accessioned |
2021-02-17T18:50:44Z |
|
dc.date.available |
2021-02-17T18:50:44Z |
|
dc.date.issued |
2021-03 |
|
dc.identifier.citation |
Dube, A., Semete-Makokotlela, B., Ramalapa, B.E., Reynolds, J. & Boury, F. 2021. Nanomedicines for the treatment of infectious diseases: Formulation, delivery and commercialization aspects. In <i>Green Synthesis in Nanomedicine and Human Health</i>. R. Glover, D. Nyanganyura, M. Mufamadi & R. Mulaudzi, Eds. S.l.: Routledge (Taylor & Francis). http://hdl.handle.net/10204/11787 . |
en_ZA |
dc.identifier.isbn |
978-0367902162 |
|
dc.identifier.isbn |
0367902168 |
|
dc.identifier.uri |
http://hdl.handle.net/10204/11787
|
|
dc.description.abstract |
The increasing prevalence of drug resistant pathogenic strains, including multi drug resistant TB along with the growing HIV and malaria resistance demand new routes of innovation for pharmaceutical drug discovery. Nanomedicine provides the opportunity to develop therapies for infectious diseases with reduced drug dosage and dose frequencies and shortened treatment duration. These combined strategies may lead to an increase in patient compliance with the goal of improving treatment outcomes and reducing occurrences of drug resistance. With these exciting opportunities, due attention has been given to the clinical translation of nanomedicines for infectious diseases applications. Examples are presented that demonstrate how nanomedicine strategies can enable the development of a wide range of therapeutic solutions to curb the rise of the infectious disease epidemic. The chapter also discusses the models for development and commercialization of medicines for infectious diseases, and presents considerations for commercialization of nanomedicines for infectious diseases. |
en_US |
dc.format |
Fulltext |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Routledge (Taylor & Francis) |
en_US |
dc.relation.uri |
https://www.amazon.com/Green-Synthesis-Nanomedicine-Human-Health/dp/0367902168 |
en_US |
dc.relation.uri |
https://www.routledge.com/Green-Synthesis-in-Nanomedicine-and-Human-Health/Glover-Nyanganyura-Mufamadi-Mulaudzi/p/book/9780367710811 |
en_US |
dc.source |
Green Synthesis in Nanomedicine and Human Health |
en_US |
dc.subject |
Infectious diseases |
en_US |
dc.subject |
Nanomedicines |
en_US |
dc.subject |
Drug delivery systems |
en_US |
dc.subject |
Liposomes |
en_US |
dc.title |
Nanomedicines for the treatment of infectious diseases: Formulation, delivery and commercialization aspects |
en_US |
dc.type |
Book Chapter |
en_US |
dc.description.edition |
1st Edition |
en_US |
dc.description.pages |
35pp |
en_US |
dc.description.placeofpublication |
London, UK |
en_US |
dc.description.note |
Copyright: 2021 Taylor & Francis. This is the preprint version of the work. For access to the published version, please visit the publisher's website. |
en_US |
dc.description.cluster |
Chemicals |
en_US |
dc.description.cluster |
Next Generation Health |
|
dc.description.impactarea |
NextGen Health Exec manager |
|
dc.description.impactarea |
Advanced Functional Materials |
|
dc.identifier.apacitation |
Dube, A., Semete-Makokotlela, B., Ramalapa, B. E., Reynolds, J., & Boury, F. (2021). Nanomedicines for the treatment of infectious diseases: Formulation, delivery and commercialization aspects. In R. Glover, D. Nyanganyura, M. Mufamadi & R. Mulaudzi. (Eds.), <i>Green Synthesis in Nanomedicine and Human Health</i> Routledge (Taylor & Francis). http://hdl.handle.net/10204/11787 |
en_ZA |
dc.identifier.chicagocitation |
Dube, A, Boitumelo Semete-Makokotlela, Bathabile E Ramalapa, J Reynolds, and F Boury. "Nanomedicines for the treatment of infectious diseases: Formulation, delivery and commercialization aspects" In <i>GREEN SYNTHESIS IN NANOMEDICINE AND HUMAN HEALTH</i>, edited by RL Glover. n.p.: Routledge (Taylor & Francis). 2021. http://hdl.handle.net/10204/11787. |
en_ZA |
dc.identifier.vancouvercitation |
Dube A, Semete-Makokotlela B, Ramalapa BE, Reynolds J, Boury F. Nanomedicines for the treatment of infectious diseases: Formulation, delivery and commercialization aspects. In Glover R, Nyanganyura D, Mufamadi M, Mulaudzi R, editors.. Green Synthesis in Nanomedicine and Human Health. [place unknown]: Routledge (Taylor & Francis); 2021. [cited yyyy month dd]. http://hdl.handle.net/10204/11787. |
en_ZA |
dc.identifier.ris |
TY - Book Chapter
AU - Dube, A
AU - Semete-Makokotlela, Boitumelo
AU - Ramalapa, Bathabile E
AU - Reynolds, J
AU - Boury, F
AB - The increasing prevalence of drug resistant pathogenic strains, including multi drug resistant TB along with the growing HIV and malaria resistance demand new routes of innovation for pharmaceutical drug discovery. Nanomedicine provides the opportunity to develop therapies for infectious diseases with reduced drug dosage and dose frequencies and shortened treatment duration. These combined strategies may lead to an increase in patient compliance with the goal of improving treatment outcomes and reducing occurrences of drug resistance. With these exciting opportunities, due attention has been given to the clinical translation of nanomedicines for infectious diseases applications. Examples are presented that demonstrate how nanomedicine strategies can enable the development of a wide range of therapeutic solutions to curb the rise of the infectious disease epidemic. The chapter also discusses the models for development and commercialization of medicines for infectious diseases, and presents considerations for commercialization of nanomedicines for infectious diseases.
DA - 2021-03
DB - ResearchSpace
DP - CSIR
ED - Glover, RL
ED - Nyanganyura, D
ED - Mufamadi, MS
ED - Mulaudzi, RB
J1 - Green Synthesis in Nanomedicine and Human Health
KW - Infectious diseases
KW - Nanomedicines
KW - Drug delivery systems
KW - Liposomes
LK - https://researchspace.csir.co.za
PY - 2021
SM - 978-0367902162
SM - 0367902168
T1 - Nanomedicines for the treatment of infectious diseases: Formulation, delivery and commercialization aspects
TI - Nanomedicines for the treatment of infectious diseases: Formulation, delivery and commercialization aspects
UR - http://hdl.handle.net/10204/11787
ER - |
en_ZA |
dc.identifier.worklist |
23945 |
en_US |